Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI South Korea ETF (EWY) Price & Performance

Citius Pharmaceuticals IncTrade
iShares MSCI South Korea ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares MSCI South Korea ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while iShares MSCI South Korea ETF trades at $174.52. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXREWY
Market Cap
$20.01M
Sector
HealthBroad Market / Factor
52-Week High
$1.82$219.20
52-Week Low
$0.48$71.22
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

iShares MSCI South Korea ETF

EWY, the iShares MSCI South Korea ETF, trades at $174.49, up 6.97% in 24 hours, with a neutral technical signal overall. Recent news highlights South Korea's semiconductor sector volatility and government support initiatives, including a $3.52 billion fund for chip materials. The ETF's performance is tied to heavyweights like Samsung and SK Hynix, which have faced sharp declines amid AI-driven market swings.

Outlook remains cautious due to sector concentration risks and foreign capital outflows, but long-term potential exists if semiconductor demand stabilizes. Investors face volatility from leveraged ETF speculation curbs and global tech sentiment shifts, requiring careful risk assessment amid mixed analyst views.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY